Alvespimycin (17-DMAG) HCl

別名: NSC 707545,BMS 826476 HCl,KOS 1022 中文名稱：阿螺旋霉素鹽酸鹽

目錄號(hào)：S1142 Purity: 99.92%

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一種有效的HSP90抑制劑，無細(xì)胞試驗(yàn)中IC50為62 nM。 Phase 2。

Alvespimycin (17-DMAG) HCl Chemical Structure

CAS: 467214-21-7

規(guī)格	價(jià)格	庫存
10mM (1mL in DMSO)	1570	現(xiàn)貨
5mg	794.94	現(xiàn)貨
25mg	2432.56	現(xiàn)貨
更大包裝
400-668-6834 [email protected]

產(chǎn)品質(zhì)控

批次：純度： 99.92%

99.92

Alvespimycin (17-DMAG) HCl相關(guān)產(chǎn)品

相關(guān)靶點(diǎn)	HSP40 HSP70 HSP90 HSP105 HSF1	點(diǎn)擊展開
相關(guān)產(chǎn)品	Tanespimycin (17-AAG) Luminespib (NVP-AUY922) Elesclomol (STA-4783) Ganetespib (STA-9090) VER155008 BIIB021 Onalespib (AT13387) NVP-BEP800 SNX-2112 KRIBB11 HA15 Zelavespib (PU-H71) HSP990 (NVP-HSP990) NMS-E973 Apoptozole XL888 PF-04929113 (SNX-5422) KNK437 VER-50589 TRC051384 Teprenone VER-49009 Pimitespib (TAS-116) JG98 Rocaglamide KW-2478 DTHIB	點(diǎn)擊展開
相關(guān)化合物庫	激酶抑制劑庫血管生成相關(guān)化合物庫 TGF-beta/Smad信號(hào)通路庫細(xì)胞骨架信號(hào)通路化合物庫抗心血管疾病化合物庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述	文獻(xiàn)信息(PMID)
CCRF-CEM	Cytotoxicity assay		72 hrs	Cytotoxicity against human paclitaxel-resistant CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay, IC50=2.5μM.	19405528
PC3	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human PC3 cells assessed as induction of HSP70 protein expression at 10 uM after 6 hrs by Western blot method	28816449
PC3	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human PC3 cells assessed as induction of Akt degradation at 10 uM after 6 hrs by Western blot method	28816449
PC3	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human PC3 cells assessed as induction of chk1 degradation at 10 uM after 6 hrs by Western blot method	28816449
HeLa	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human HeLa cells assessed as induction of Akt degradation at 10 uM after 6 hrs by Western blot method	28816449
HeLa	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human HeLa cells assessed as induction of chk1 degradation at 10 uM after 6 hrs by Western blot method	28816449
Ma1	Cytotoxicity assay		72 hrs	Cytotoxicity against HGF-induced erlotinib-resistant human Ma1 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50=0.01μM.	26844689
PC9	Cytotoxicity assay		72 hrs	Cytotoxicity against HGF-induced erlotinib-resistant human PC9 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50=0.01μM.	26844689
SKBR3	Antiproliferative assay		48 hrs	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay, IC50=3.11μM.	24763261
NCI-H1299	Function assay		12 hrs	Reduction in oxygen consumption rate in human NCI-H1299 cells incubated for 12 hrs	25383915
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by celltiter-glo assay, IC50=0.23μM.	19405528
CCRF-CEM	Cytotoxicity assay		72 hrs	Cytotoxicity against human CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay, IC50=0.54μM.	19405528
MCF7	Antiproliferative assay		48 hrs	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay, IC50=0.8μM.	24763261
HCT116	Antiproliferative assay		48 hrs	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay, IC50=1.21μM.	24763261
SKBR3	Antiproliferative assay		48 hrs	Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50=1.34μM.	24582477
HCT116	Antiproliferative assay		48 hrs	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50=0.78μM.	24582477
LN229-Lux	Function assay	2.5 to 10 uM	1 hr	Inhibition of luciferase activity in human LN229-Lux cells at 2.5 to 10 uM incubated for 1 hr under normoxia followed by 24 hrs under hypoxia by reporter gene assay	22746274
NCI-H1299	Function assay		24 hrs	Inhibition of human HSP90 in human NCI-H1299 cells assessed as Akt degradation after 24 hrs by luminex assay, IC50=0.1μM.	21438541
HCT116	Cytotoxicity assay			Cytotoxicity against human HCT116 cells by Alamar blue assay, IC50=0.05μM.	20662534
Hep3B	Function assay		16 hrs	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA, IC50=0.079μM.	20469887
SKBR3	Cytotoxicity assay		72 hrs	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay, IC50=0.024μM.	19405528
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by celltiter-glo assay, IC50=0.068μM.	19405528
SKOV3	Cytotoxicity assay		72 hrs	Cytotoxicity against human SKOV3 cells after 72 hrs by celltiter-glo assay, IC50=0.22μM.	19405528
Hep3B	Function assay		16 hrs	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA, IC50=0.0795μM.	19072214
HCT116	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCT116 cells after 72 hrs, IC50=0.057μM.	19231864
SKBR3	Cytotoxicity assay		72 hrs	Cytotoxicity against human SKBR3 cells after 72 hrs, IC50=0.058μM.	19231864
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs, IC50=0.071μM.	19231864
SKOV3	Cytotoxicity assay		72 hrs	Cytotoxicity against human SKOV3 cells after 72 hrs, IC50=0.122μM.	19231864
SKBR3	Cytotoxicity assay		72 hrs	Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol, IC50=0.23μM.	19231864
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol, IC50=0.862μM.	19231864
NCI-H596	Cytotoxicity assay		72 hrs	Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs, IC50=1.1μM.	19231864
MDA468	Cytotoxicity assay		72 hrs	Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs, IC50=1.6μM.	19231864
SKBR3	Function assay			Binding affinity to Hsp90 in human SKBR3 cells, IC50=0.024μM.	19017562
Hep3B	Function assay		30 mins	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis, IC50=0.0572μM.	19072214
HeLa	Cytotoxicity assay			Cytotoxicity against human HeLa cells by MTT assay, IC50=2.06μM.	18359631
HeLa	Function assay			Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells, IC50=0.15μM.	18359631
AGS	Function assay			Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay, IC50=0.0036μM.	18359631
NCI-H526	Function assay	1 uM	96 hrs	Inhibition of HSP90-mediated proliferation of human NCI-H526 cells at 1 uM after 96 hrs by sulforhodamine B assay	17603540
NCI-H526	Function assay	1 uM	24 hrs	Binding affinity to HSP90 in human NCI-H526 cells at 1 uM after 24 hrs by fluorescence polarization assay	17603540
AGS	Function assay		24 hrs	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay, IC50=16μM.	17583950
Hep3B	Function assay		16 hrs	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay, IC50=0.061μM.	17583950
AGS	Function assay		16 hrs	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay, IC50=0.036μM.	17583950
SKOV3	Function assay			Degradation of Her2 in SKOV3 cells, EC50=0.046μM.	16854066
SKOV3	Function assay			Upregulation of Hsp70 in SKOV3 cells, EC50=0.014μM.	16854066
SKBR3	Function assay			Degradation of Her2 in SKBR3 cells, EC50=0.008μM.	16854066
SKBR3	Function assay			Upregulation of Hsp70 in SKBR3 cells, EC50=0.004μM.	16854066
SKBr3	Cytotoxicity assay			Cytotoxicity against SKBr3 cells, IC50=0.024μM.	16165354
MDA-MB-231	Cytotoxicity assay			Cytotoxicity against human MDA-MB-231 cells by MTT assay, IC50=0.0058μM.	18929486
A2058	Function assay			Inhibition of Hsp90 in human A2058 cells, EC50=0.0079μM.	18929486
MDA-MB-231	Function assay			Inhibition of Hsp90 in human MDA-MB-231 cells assessed as Akt degradation, IC50=0.0176μM.	18929486
A2058	Function assay			Inhibition of Hsp90 in human A2058 cells assessed as Akt degradation, IC50=0.0243μM.	18929486
HuH7	Antiviral assay		3 days	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis, EC50=0.0012μM.	18936191
HuH7	Antiviral assay		3 days	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis, EC50=0.0031μM.	18936191
MDA-MB-231	Function assay			Inhibition of Hsp90 in human MDA-MB-231 cells assessed as her2 degradation, IC50=0.0045μM.	18929486
Hep3B	Function assay		30 mins	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis, IC50=0.057μM.	20469887
HeLa	Function assay	10 uM	6 hrs	Inhibition of HSP90 in human HeLa cells assessed as induction of HSP70 protein expression at 10 uM after 6 hrs by Western blot method	28816449
SKBR3	Function assay			Inhibition of Hsp90 in human SKBR3 cells, IC50=0.024μM.	26844689
A231	Antiproliferative assay		48 hrs	Antiproliferative activity against human A231 cells after 48 hrs by MTT assay, IC50=0.17μM.	24763261
MCF7	Antiproliferative assay		48 hrs	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50=0.39μM.	24582477
AGS	Cytotoxicity assay			Cytotoxicity against human AGS cells by MTT assay, IC50=16μM.	18359631
A2058	Cytotoxicity assay			Cytotoxicity against human A2058 cells by MTT assay, IC50=0.0021μM.	18929486
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl是一種有效的HSP90抑制劑，無細(xì)胞試驗(yàn)中IC50為62 nM。 Phase 2。

特性

17-DMAG是抗生素Geldanamycin 的合成衍生物，比現(xiàn)有抗生素具有較低的肝毒性，比相似衍生物17-AAG效果和有效性更強(qiáng)。

靶點(diǎn)

HSP90 ^[1]
(Cell-free assay)

62 nM

體外研究(In Vitro)
體外研究活性	熒光偏振（FP）為基礎(chǔ)的競(jìng)爭(zhēng)性結(jié)合實(shí)驗(yàn)中，17-DMAG作用于人類 Hsp90比 17-AAG（IC50 為 119 nM）效果高2倍，IC50為 62 nM。17-DMAG作用于過量表達(dá)Hsp90“服務(wù)蛋白” Her2的SKBR3和 SKOV3細(xì)胞,下調(diào)Her2，EC50分別為8 nM和 46 nM, 且誘導(dǎo) Hsp70，EC50分別為 4 nM和 14 nM,結(jié)果產(chǎn)生顯著的毒性，GI50分別為 29 nM 和32 nM。^[1] 17-DMAG和 Vorinostat 聯(lián)用，通過顯著降低cyclin D1和CDK4, 及c-Myc, c-RAF 和AKT水平，協(xié)同誘導(dǎo)培養(yǎng)的MCL細(xì)胞和原發(fā)性 MCL 細(xì)胞凋亡。^[3]17-AAG 只有效作用于慢性淋巴細(xì)胞白血病 (CLL) 細(xì)胞的IKKβ，而17-DMAG 處理，有效導(dǎo)致Hsp90 客戶蛋白IKKα 和 IKKβ的消耗,導(dǎo)致 NF-κB p50/p65 DNA結(jié)合減少，NF-κB 靶基因轉(zhuǎn)錄降低，及caspase依賴性凋亡降低。通過靶向作用于NF-κB 家族，17-DMAG作用于CLL細(xì)胞而不是正常T細(xì)胞或NK細(xì)胞，選擇性調(diào)節(jié)毒性，這種作用存在劑量和時(shí)間依賴性。^[5]
激酶實(shí)驗(yàn)	熒光偏振（FP）為基礎(chǔ)的競(jìng)爭(zhēng)性結(jié)合實(shí)驗(yàn)
激酶實(shí)驗(yàn)	實(shí)驗(yàn)使用氟化硼亞甲基二吡咯(BODIPY)標(biāo)記的Geldanamycin類似物 (BODIPY-AG) 作為探針，根據(jù)探針與蛋白結(jié)合情況，測(cè)定熒光偏振。從 HeLa細(xì)胞中分離活性人類Hsp90 蛋白 (α + β 亞型)。 BODIPY-AG 溶液在FP 實(shí)驗(yàn) buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl₂, 0.01% NP-40, 0.1 mg/mL 新鮮牛γ-球蛋白 (BGG), 1.0 mM 新鮮DTT,和蛋白酶抑制劑，溶于)中新鮮制備。通過10 μL每組含 BODIPY-AG 和Hsp90的溶液，與連續(xù)稀釋的 17-DMAG（在 FP 實(shí)驗(yàn) buffer中新鮮制備）混合，而獲得競(jìng)爭(zhēng)性曲線。終濃度為10 nM BODIPY-AG, 40 或 60 nM Hsp90,不同濃度 17-DMAG (0.10 nM-10 μM), 和 ≤0.25% DMSO 在384孔板中混合。30^oC下溫育3小時(shí)后, 在EnVision 2100多標(biāo)記酶標(biāo)儀上測(cè)定熒光各向異性(γEx = 485 nm, γEm = 535 nm) 。從競(jìng)爭(zhēng)曲線中獲得17-DMAG的IC50值。
細(xì)胞實(shí)驗(yàn)	細(xì)胞系	慢性淋巴細(xì)胞白血病(CLL)
	濃度	溶于DMSO,終濃度為~1 μM
	孵育時(shí)間	24, 或48小時(shí)
	方法	使用不同濃度17-DMAG 處理細(xì)胞24,或48小時(shí)。為了測(cè)量毒性, 加如MTT試劑，實(shí)驗(yàn)板再溫育24小時(shí)，然后使用分光光度法測(cè)量。通過膜聯(lián)蛋白 V-異硫氰酸熒光素和碘化丙啶(PI)染色測(cè)定凋亡。
實(shí)驗(yàn)圖片	檢測(cè)方法	檢測(cè)指標(biāo)	實(shí)驗(yàn)圖片	PMID
	Western blot	HSP90 / HSP70 p-Akt / Survivin / MMP2 PARP / Cleaved caspase-3 / Cleaved caspase-8 / Cleaved caspase-9 / PUMA p-ALK / ALK / p-Akt / Akt / p-ERK / ERK α-Tax / α-IKKα / α-IKKβ/ α-NEMO / α-TBK1 / α-p65 / α-p50		28915605
	Growth inhibition assay	Cell proliferation		28915605

體內(nèi)研究(In Vivo)
體內(nèi)研究活性	17-DMAG按5 mg/kg 或 25 mg/kg處理，每周三次，顯著降低 TMK-1 移植瘤生長(zhǎng)，通過顯著降低血管面積和增殖腫瘤細(xì)胞數(shù)。^[2]與抑制FAK信號(hào)一致，17-DMAG 按 25 mg/kg劑量處理小鼠，每周三次，顯著抑制腫瘤生長(zhǎng)，及ME180 和SiHa 移植瘤的轉(zhuǎn)移。^[4]17-DMAG 按10 mg/kg 劑量處理TCL1-SCID移植鼠模型，處理16天，顯著降低白細(xì)胞數(shù)，且延長(zhǎng)壽命。^[5]
動(dòng)物實(shí)驗(yàn)	Animal Models	移植TCL1 白血病細(xì)胞的SCID小鼠
	Dosages	10 mg/kg
	Administration	腹腔注射，每周5次

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT00780000	Terminated	Breast Cancer	Bristol-Myers Squibb	April 2008	Phase 2
NCT00248521	Unknown status	Unspecified Adult Solid Tumor Protocol Specific	Institute of Cancer Research United Kingdom\|National Cancer Institute (NCI)	October 2005	Phase 1

參考文獻(xiàn)
https://pubmed.ncbi.nlm.nih.gov/16854066/ https://pubmed.ncbi.nlm.nih.gov/17363505/ https://pubmed.ncbi.nlm.nih.gov/19440035/ https://pubmed.ncbi.nlm.nih.gov/19458065/ https://pubmed.ncbi.nlm.nih.gov/20351313/ + 展開

參考文獻(xiàn)

https://pubmed.ncbi.nlm.nih.gov/16854066/
https://pubmed.ncbi.nlm.nih.gov/17363505/
https://pubmed.ncbi.nlm.nih.gov/19440035/

https://pubmed.ncbi.nlm.nih.gov/19458065/
https://pubmed.ncbi.nlm.nih.gov/20351313/

+ 展開

化學(xué)信息&溶解度

分子量	653.21	分子式	C₃₂H₄₈N₄O₈•HCl
CAS號(hào)	467214-21-7	SDF	Download Alvespimycin (17-DMAG) HCl SDF
Smiles	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)C)OC)OC(=O)N)C)C)O)OC.Cl
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1個(gè)月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 100 mg/mL ( (153.09 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 131 mg/mL ( (200.54 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 100 mg/mL ( (153.09 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解配方批次：現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑				動(dòng)物體內(nèi)配方計(jì)算器
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測(cè)。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測(cè)試。	5.000mg/ml (7.65mM)	以 1 mL 工作液為例,取50μL100mg/ml的澄清DMSO儲(chǔ)備液加到400μLPEG300中,混合均勻使其澄清;向上述體系中加入50μLTween80,混合均勻使其澄清;然后繼續(xù)加入500μLddH2O定容至1mL。工作液請(qǐng)現(xiàn)配現(xiàn)用!
澄清溶液	5% DMSO 1 95% Corn oil 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測(cè)。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測(cè)試。	0.300mg/ml (0.46mM)	以1 mL工作液為例，取50μL 6mg/ml的澄清DMSO儲(chǔ)備液加到950μL玉米油中，混合均勻。工作液請(qǐng)現(xiàn)配現(xiàn)用！

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）

給藥劑量 mg/kg 動(dòng)物平均體重 g 每只動(dòng)物給藥體積 μL 動(dòng)物數(shù)量只

第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問題，請(qǐng)給我們留言。

* 必填項(xiàng)

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Alvespimycin (17-DMAG) HCl

產(chǎn)品質(zhì)控

Alvespimycin (17-DMAG) HCl相關(guān)產(chǎn)品

相關(guān)信號(hào)通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

生物活性

化學(xué)信息&溶解度

實(shí)驗(yàn)計(jì)算

技術(shù)支持